查看文章

The aim of this study was to investigate the influence of clinical and genetic factors on response to tocilizumab (TCZ) response, remission, low disease activity (LDA) and DAS28 improvement.

A retrospective cohort study in 79 RA patients treated with TCZ during 6/18 months of therapy was conducted. CD69(rs11052877), GALNT18(rs4910008), CLEC2D(rs1560011), KCNMB1(rs703505), ENOX1(rs9594987), rs10108210, and rs703297 gene polymorphisms, identified in a recent GWAS as putative predictors of TCZ response, were analysed.

Variables independently associated to satisfactory EULAR response at 6 months were GALNT18-CC genotype (OR_CC/T-:12.8; CI_95%:1.5,108.7; p = 0.02), CD69 gene polymorphism (OR_AA/GG:17.2; CI_95%:2.5,119.6; p = 0.004) and lower number of previous biological therapy, BT (OR: 0.45; CI_95%:0.3, 0.7; p = 0.001). The factors independently associated to higher remission …